刘滔 - 浙江大学

个人简介

刘滔，副教授，博士生导师，入选浙江省151人才工程。于浙江大学获得医学博士学位，曾在法国巴黎高师进行博士后研究。承担国家级及省级课题20余项，包括国家科技重大专项、国家自然科学基金面上项目、浙江省自然科学基金重点项目、面上项目、卫生部科研基金、中科院战略性先导科技专项等多项研究项目。在JMC、CC、Leukemia、EJMC、CMC等SCI收录刊物上发表专业论文60余篇。申请国家发明专利40余项，PCT专利3项，授权28项（包括美国专利3项、欧洲专利3项、加拿大专利3项、日本专利3项和韩国专利1项）。获浙江省科技进步二等奖、三等奖及浙江省医药科学技术创新奖一等奖多次。参编《药物化学》、《高等药物化学》、《新药研发案例研究》等多部著作。

研究领域

药物化学近年来一直以新型候选药物的研发为核心，将计算机辅助药物设计、理性药物设计及“优势骨架”导向的研究策略整合，重点开展靶向恶性肿瘤、艾滋病等重大疾病的新药研究工作，已发现多个靶向于蛋白酶体、CHK1、FLT3和CCR5等颇具临床开发前景的候选药物。其中CHK1抑制剂候选药物PY34AC已于2020年8月获得NMPA的临床研究许可，另有2个PCC正启动系统临床前研究，争取2023年底pre-IND。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Mei Sun, Chang Wang, Peipei Wang, Qingqing Ye, Yubo Zhou*, Jia Li*, Tao Liu*. Design, synthesis, and evaluation of pyrido.[3,4-b]pyrazin-2(1H)-one derivatives as potent FLT3 inhibitors. Bioorganic & Medicinal Chemistry 2023, 79,117155. Kailong Jiang, Xuemei Li, Chang Wang, Xiaobei Hu, Peipei Wang, Lexian Tong, Yutong Tu, Beijing Chen, Tingting Jin, Tao Wang, Hanlin Wang, Yubing Han, Renzhao Gui, Jianmin Yang, Tao Liu*, Jia Li*, Yubo Zhou*. Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia. Leukemia 2023, 37, 539-549. Minjie Deng, Peipei Wang, Xiubing Long, Gaoya Xu, Chang Wang, Jia Li*, Yubo Zhou*, Tao Liu*. Design, Synthesis, and Biological Evaluation of 2-Aminothiazole Derivatives as Novel Checkpoint Kinase 1 (CHK1) Inhibitors. ChemMedChem 2023,18, e202200664. Qingqing Ye, Jingkun Ma, Peipei Wang, Chang Wang, Mei Sun, Yubo Zhou*, Jia Li*, Tao Liu*. Discovery of pyrido[4,3-d]pyrimidinone derivatives as novel Wee1 inhibitors. Bioorganic & Medicinal Chemistry 2023, 87, 117312 Lexian Tong, Peipei Wang, Xuemei Li, Xiaowu Dong, Xiaobei Hu, Chang Wang, Tao Liu*, Jia Li*, Yubo Zhou*. Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT. Journal of Medicinal Chemistry 2022, 65, 3229-3248. Tingting Jin, Lei Xu, Peipei Wang, Xiaobei Hu, Runyuan Zhang, Zhiqi Wu, Wenxin Du, Weijuan Kan, Kun Li, Chang Wang, Yubo Zhou*, Jia Li*, Tao Liu*. Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino) picolinonitrile. Journal of Medicinal Chemistry 2021, 64, 15069-15090. Xuemei Li, Duidui Hong, Mengmeng Zhang, Lei Xu, Yubo Zhou*, Jia Li*, Tao Liu*. Development of peptide epoxyketones as selective immunoproteasome inhibitors. European Journal of Medicinal Chemistry 2021, 221, 113556. LexianTong, PinraoSong, KailongJiang, LeiXu, TingtingJin, PeipeiWang, XiaobeiHu, SuiFang, AnhuiGao, YuboZhou, Tao Liu*, JiaLi*, YongzhouHu*. Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies. European Journal of Medicinal Chemistry 2019, 173, 44-62. Daqiang Li, Xiaotuan Zhang, Xiaodong Ma, Lei Xu, Jianjun Yu, Lixin Gao, Xiaobei Hu, Jiankang Zhang, Xiaowu Dong, Jia Li, Tao Liu*, Yubo Zhou*, Yongzhou Hu*. Development of macrocyclic peptides containing epoxyketone with oral availability as proteasome inhibitors. Journal of Medicinal Chemistry 2018, 61 (20), 9177–9204. Tao Liu, DaQiang Li, SiYu Wang, YongZhou Hu, XiaoWu Dong, XinYuan Liu, ChiMing Che. Straightforward installation of carbon-halogen, carbon-oxygen and carbon-carbon bonds within metal-organic frameworks (MOF) via palladium-catalysed direct C-H functionalization. Chemical Communications 2014, 50(87), 13261-13264.